Procter & Gamble Health Reports Q1 Results: Sales Up 7%, Profit After Tax Jumps 45%
Mumbai, August 6, 2026: Procter & Gamble Health Ltd. today announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported sales of ₹356 crores, marking a 7% increase compared to the previous year. Reported Profit After Tax (PAT) stood at ₹96 crores, reflecting a significant rise of 45%.The strong performance in both top-line and bottom-line figures was attributed to robust brand fundamentals, superior retail execution, and positive consumer response to new product innovations. The increase in profitability was driven by growth in sales, strengthened go-to-market capabilities, and improved supply chain management. Furthermore, the reported PAT includes one-time proceeds generated from the sale of an immovable asset. Operational Profit After Tax (PAT), excluding these non-recurring proceeds, reached ₹72 crores, a 9% increase year-over-year.
Milind Thatte, Managing Director of P&G Health India, commented on the results, stating that the company is pleased to commence Financial Year 2026-2027 on a strong foundation. He noted that the sustained growth momentum is enabled by consumer response to science-backed innovations and new consumer communication initiatives, alongside strengthened go-to-market and supply chain capacities. Mr. Thatte emphasized that the company is delivering balanced value creation for all stakeholders through its strategy, which centers on a focused portfolio of quality and trusted brands.
Procter & Gamble Health Limited specializes in manufacturing and marketing vitamins, minerals, and supplements (VMS) products aimed at improving quality of life. The product portfolio includes key brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. P&G serves consumers globally with its diverse range of leadership brands in approximately 70 countries.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.